


# Microbial escape of innate immunity


Dubrovnik 1.10.2010

Seppo Meri  
Haartman Institute  
University of Helsinki, Finland

## Innate immune defence mechanisms



## Complement activation



Complement inhibitors: *C4bp*, *factor H*  
MAC, membrane attack complex



## Borrelia

Spirochete

Internal flagella – motile

~10µm long

- Animal disease
- Lyme disease
- Relapsing fever



## How can *Borrelia burgdorferi* escape immune attack?

Borreliae can survive in blood and tissues for months

Slow and inefficient phagocytosis

Can vary surface antigens

Basis of serum resistance?


Which molecules are responsible?

Differences between strains?


Regulation of expression ?

## *Borrelia burgdorferi* binds factor H via two proteins

Body temperature (37°C) and host adaptation increase the expression of fH binding molecules





Allitalo et al, I&I 2001, JI 2002, JI 2004; Hellwege et al JBC 2001




## Factor H binding by cp32-plasmid-encoded OspE surface proteins from *B. burgdorferi*

- The OspE/p21/ErpA family proteins (but not OspF or Elps) show factor H binding
- A single strain can have multiple paralogous OspE proteins encoded on separate cp32 plasmids
- The OspE proteins may constitute a family of virulence factors expressed in different hosts



Allitalo et al, J Immunol, 2002, 2004

*B. garinii* is serum sensitive *in vitro* yet it can cause neuroborreliosis - why ?



Borrelial factor H binding proteins are produced in patients but not under *in vitro* conditions

## Meningococcal sepsis and meningitis

- caused by 9 main capsule types, most common: A, B, C, W135, Y
- incidence:  $\approx 1/100\ 000$ /year
- mortality: 10-20% (WHO: 1.2 mill. deaths/year)
- infants (< 2y) the major risk group
- carriage up to 20% in young adults

## Complement and meningococcus

- complement deficiencies (H, P, D, C6, C7, C8, C9) predispose to meningococcal disease (risk  $\approx 1000\times$ )
- GWAS: meningococcal meningitis linked to FH, FHR-3 (chr. 1)
- in complement deficiency meningococcal disease may recur, but is usually milder


## Complement evasion by meningococcus

- binding of C4bp by PorA (Jarva et al, JI, 2005)
- binding of factor H by GNA1870 (Madico et al, JI, 2006)

## Meningococcal vaccines

- Existing vaccines
  - capsule vaccines (A, C, W135, Y)
- Problems with menB
  - poorly immunogenic ( $\alpha$ 2-8 polysialic acid capsule)
  - potentially cross-reactive with human neuronal tissue (Finne et al, 1983)
- potential
  - outer membrane vesicles (OMVs)
  - new antigens from "reverse vaccinology" (Giuliani et al, 2006)

New ways to make vaccines



## New meningococcal vaccines

### 1. rMenB (Novartis)

- NadA (Neisserial adhesin A)
- FHBP (GNA1870; factor H binding protein)
- GNA2091
- GNA2132 (Neisserial heparin binding antigen)
- GNA1030
  - now in phase 2b and 3 trials in infants, toddlers and adolescents

### 2. rLP2086 (Wyeth)


- 2 (out of 3) variants of FHBP
- in phase 1 and 2 trials in infants

## Challenges for a men B vaccine

1. Immunogenicity in infants
2. Variations in the vaccine antigens
3. Strong binding of factor H by FHBP
  - masking of important epitopes

### Microbial inhibitors of complement as vaccine candidates


Microbe	Interacting protein	Key structural feature	Mechanism of action	Variability	Potential as a vaccine
GAS	M-protein	$\alpha$	H, C4bp	+++	++
GBS	$\beta$ (Bac)	$\alpha$	H	+	+++
<i>S. pneumoniae</i>	PspC	$\alpha$	H	+++	++
<i>S. aureus</i>	Sbi	$\alpha$	C3		
<i>B. burgdorferi</i>	OspE CspA	$\alpha$	H H	+++ +	+ ++
<i>B. pertussis</i>	FHA	$\beta$	C4bp	+	++
<i>Y. enterocolitica</i>	YadA Ail	$\alpha$ $\beta$	H, C4bp H, C4bp	++ ++	+ -
<i>Y. pestis</i>	Pla	$\beta$	E	+	$\pm$
<i>S. typhimurium</i>	Rck PgtE	$\beta$ $\beta$	TCC/FH E	+ +	$\pm$ $\pm$
<i>N. meningitidis</i>	GNA1870 PorA	$\beta$ $\beta$	H C4bp	++ ++	++ ++
<i>N. gonorrhoeae</i>	Por1A Por1B	$\beta$ $\beta$	H, C4bp C4bp	+ +	+ +



$\alpha$ , alpha-helical/coiled-coil;  $\beta$ , beta-barrel; E, enzymatic activity

Meri et al, Vaccine, 2008

## *Y. enterocolitica* surface



Kirjavainen et al, PLOS Pathog 2008




## Pla of *Yersinia pestis*

■ outer membrane  $\beta$ -barrel protein


■ homologues in omptin family e.g.

- PgtE of *Salmonella enterica*
- OmpT of *Escherichia coli*



Kukkonen et al. (2004) Mol. Microbiol. 51: 215-225

## Microbial tools for complement evasion



## Acknowledgements

### • Helsinki, Finland

Hanna Jarva, Sakari Jokiranta, Derek Ho, Taru Meri, Antti Alitalo, Jaana Panelius, Timo Korhonen, Rauna Riva, Päivi Ramu, Nathalie Friberg, Kaarina Lähteenmäki, Vesa Kirjavainen, Marta Biedzka-Sarek, Mikael Skurnik, Markus Lehtinen, Arnab Bhattacharjee, Tommi Kajander, Adrian Goldman

### • Malmö, Sweden

Anna Blom, Barbara Albiger

### • Würzburg, Germany

Markus Jördens, Ulrich Vogel

### • Boston, US

Sanjay Ram, Peter Rice

### • Oklahoma City, US

Darrin Akins, Chad Brooks

### • Milan, Italy

Livija Deban, Barbara Bottazzi, Cecilia Garlanda, Alberto Mantovani

### • Novartis, Siena, Italy

Kate Seib, Mariagrazia Pizza, Rino Rappuoli